Scholar Rock Holding Corporation
$47.8
▲
1.34%
2026-04-21 09:36:00
www.scholarrock.com
NMS: SRRK
Explore Scholar Rock Holding Corporation stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$5.49 B
Current Price
$47.8
52W High / Low
$51.62 / $27.07
Stock P/E
—
Book Value
$2.26
Dividend Yield
—
ROCE
-110.26%
ROE
-1.23%
Face Value
—
EPS
$-3.29
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
289
Beta
0.69
Debt / Equity
44.37
Current Ratio
6.95
Quick Ratio
6.95
Forward P/E
-23.29
Price / Sales
—
Enterprise Value
$5.48 B
EV / EBITDA
-14.31
EV / Revenue
—
Rating
Strong Buy
Target Price
$57.43
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Daré Bioscience, Inc. | $2.87 | — | $41.79 M | — | -154.2% | 845.53% | $9.19 / $1.27 | $0.2 |
| 2. | Climb Bio, Inc. | $8.97 | — | $437.55 M | — | -42.23% | -32.15% | $9.4 / $1.13 | $3.36 |
| 3. | Tiziana Life Sciences Ltd | $1.21 | — | $143.81 M | — | -401.27% | -2.32% | $2.6 / $0.87 | $0.08 |
| 4. | Inovio Pharmaceuticals, Inc. | $1.18 | — | $96.69 M | — | -283.35% | -1.83% | $2.98 / $1.03 | $0.35 |
| 5. | Milestone Pharmaceuticals Inc. | $2.04 | — | $247.1 M | — | -62.4% | -2.3% | $3.06 / $0.77 | $0.34 |
| 6. | Cybin D/B/A Helus Pharma | $5.61 | — | $1.92 M | — | -60.35% | -55.89% | $12.7 / $5.9 | $5.49 |
| 7. | IDEAYA Biosciences, Inc. | $33.6 | — | $2.95 B | — | -15.17% | -10.92% | $39.28 / $16.07 | $11.65 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -91.9 M | -103.55 M | -112.11 M | -77.09 M | -69.36 M | — |
| Net Profit | -90.97 M | -102.22 M | -110.03 M | -74.72 M | -66.45 M | — |
| EPS in Rs | -0.79 | -0.89 | -0.96 | -0.65 | -0.58 | -0.66 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 33.19 M |
| Operating Profit | -384.64 M | -252.05 M | -171.29 M | -134.37 M |
| Net Profit | -377.94 M | -246.29 M | -165.79 M | -134.5 M |
| EPS in Rs | -3.29 | -2.14 | -1.44 | -1.17 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 404.27 M | 474.92 M | 311.04 M | 358.17 M |
| Total Liabilities | 158.78 M | 106.29 M | 85.82 M | 97.93 M |
| Equity | 245.49 M | 368.63 M | 225.22 M | 260.24 M |
| Current Assets | 385.15 M | 451.17 M | 288.19 M | 328.02 M |
| Current Liabilities | 55.42 M | 46.94 M | 32.74 M | 36.39 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -300.04 M | -200.95 M | -145.23 M | -132.69 M |
| Investing CF | 218.69 M | -76.06 M | 41.14 M | -171.7 M |
| Financing CF | 228.4 M | 353.03 M | 102.57 M | 194.83 M |
| Free CF | -300.64 M | -201.05 M | -145.3 M | -133.76 M |
| Capex | -0.6 M | -0.1 M | -0.07 M | -1.06 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | -100% | — |
| Earnings Growth % | -53.45% | -48.56% | -23.26% | — |
| Profit Margin % | — | — | — | -405.21% |
| Operating Margin % | — | — | — | -404.81% |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | -395.82% |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.